A pharmaceutical composition containing juglone and ivermectin for preventing and treating animal acariasis and its application

By combining walnutone with ivermectin, a pharmaceutical composition for treating animal mite diseases is solved, and the drug resistance and environmental pollution caused by ivermectin alone is achieved, and more efficient mite killing and hair are achieved. Recovery reduces the use of chemical drugs and environmental pollution.

CN116196322BActive Publication Date: 2024-11-08LANZHOU INST OF ANIMAL SCI & VETERINARY PHARMA OF CAAS
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310131771.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-18
Publication Date
2024-11-08
Estimated Expiration
2043-02-18

AI Technical Summary

Technical Problem

The long-term use of ivermectin for the treatment of animal mite diseases has led to increased drug resistance, reduced therapeutic effect, and environmental pollution problems.

Method used

Combining walnutone with ivermectin, through the formulation of different mass ratios, forms a pharmaceutical composition for preventing or treating animal mite diseases, for acaricidal and promoting fur recovery, reducing drug resistance and environmental pollution .

Benefits of technology

This composition significantly improves the prevention and treatment effect of animal mite diseases, extends the treatment endurance period, reduces the dosage of ivermectin, avoids drug resistance and environmental pollution caused by the use of a single compound, and enhances the mites mortality rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GHA0000007389780000041
    Figure GHA0000007389780000041
  • Figure GHA0000007389780000051
    Figure GHA0000007389780000051
Patent Text Reader

Abstract

The invention belongs to the field of veterinary medicine, and specifically relates to a pharmaceutical composition for preventing or treating animal mite disease and an application thereof. The pharmaceutical composition is prepared by dissolving a raw material drug in an organic solvent, the raw material drug comprises juglone and ivermectin, and the mass ratio of juglone to ivermectin is 1:10, 1:1 or 5:1. In the pharmaceutical composition of the invention, juglone and ivermectin are combined for the first time. Compared with a single agent, the combined use of the composition for treating animal mite disease has a synergistic effect in killing mites, improves the prevention and control effect, reduces the loss caused by mites, promotes the recovery of damaged fur, reduces fur damage, can avoid potential drug resistance caused by the use of a single compound, and reduces residues and environmental pollution.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of veterinary medicines, and particularly relates to a pharmaceutical composition containing juglone and ivermectin for preventing and treating animal acariasis and application thereof. Background Art

[0002] Animal mite disease is a chronic external parasitic disease of animals caused by mites parasitizing the surface of animals. Its pathogens are scabies and itch mites. It mainly occurs in late autumn, winter and early spring. It is transmitted through direct or indirect contact between sick animals and healthy animals. It is widely found in cattle, sheep, horses, dogs, rabbits, chickens and other animals. It can also be transmitted to humans. The infection rate and morbidity rate are high in pastoral areas, agricultural and pastoral areas and large-scale farms. The main manifestations of the disease in animals are decreased or lost appetite, weight loss, severe itching, exudative dermatitis, hair loss and high infectivity, which seriously affect the production performance and economic value of animals and seriously restrict the healthy development and economic benefits of animal husbandry.

[0003] At present, the drugs used to treat animal mite diseases are mainly chemically synthesized and antibiotic drugs. Ivermectin is a highly effective, broad-spectrum antibiotic antiparasitic agent. The mechanism of action is to interfere with the neurophysiological activities of pests, stimulate the release of γ-aminobutyric acid, act on the nerve-muscle junction, increase the release of chloride ions, inhibit the information transmission of the nerve junction, and cause paralysis and poisoning death of pests and mites. Ivermectin is widely used in the treatment of sheep mite disease (see the literature Sharula. Ivermectin injection for the treatment of sheep mite disease [J]. Veterinary Guide, 2020 (21): 113.) and canine mite disease (see the literature Guo Yuanyin et al. Ivermectin treatment effect of canine mite disease [J]. Today's Animal Husbandry and Veterinary Medicine, 2021, 37 (10): 95.). However, due to long-term single use, it is easy to develop drug resistance, resulting in increased dosage, reduced therapeutic effect, shortened duration of effect, and other problems, which is not conducive to public health, food safety and ecological environment. For example, a dog took 5 mL of ivermectin injection orally and showed symptoms of poisoning 0.5 hours later. When arriving at the scene, it was found that the dog had already shown symptoms of vomiting, ataxia, salivation, and dilated pupils (see Zhang Yong et al. Diagnosis and treatment of a near-death case of canine ivermectin poisoning [J]. Shandong Animal Husbandry and Veterinary Medicine, 2020, 41(04):33.). A veterinarian at a pig farm increased the dose of ivermectin by 3 to 4 times, resulting in the death of the pigs from poisoning; however, some studies have shown that pigs have a strong tolerance to ivermectin. After a 5-fold dose of ivermectin was injected subcutaneously every day for 5 consecutive days, no typical symptoms of poisoning appeared. On the 6th to 8th day, an 8-fold dose was injected, resulting in typical symptoms of poisoning on the 7th day and death on the 8th day (see Cao Kefei et al. Research progress in the prevention and control of swine parasitic diseases with ivermectin [J]. Jilin Animal Husbandry and Veterinary Medicine, 2020, 41(04):3-5.). At the same time, with the extensive use and even abuse of ivermectin in recent years, some parasites have developed a certain degree of resistance to the drug, which has seriously affected the clinical anthelmintic effect of ivermectin. The digestive tract nematodes of sheep in a natural pasture in Hulunbuir, Inner Mongolia have developed strong resistance to ivermectin and albendazole (see the literature Luo Xiaoping et al. Study on the effect of three anthelmintics on the killing of gastrointestinal nematodes of sheep in Hulunbuir, Inner Mongolia [J]. Chinese Journal of Veterinary Medicine, 2017, 53 (10): 35-37.). Some studies have also shown that the average infection rate of gastrointestinal nematodes in 10 grazing sheep herds in eastern Inner Mongolia was as high as 79.2%. After drug treatment, it was found that the gastrointestinal nematodes of these 10 grazing sheep herds had different degrees of resistance to avermectin, ivermectin, and albendazole. Only levamisole had a good anthelmintic effect on gastrointestinal nematodes in the area (see the literature Frontal Yeledeg et al. Investigation on the infection and drug resistance of digestive tract nematodes in sheep in Wushi Banner [J]. Chinese Journal of Veterinary Science, 2018, 48(06): 735-742.).Therefore, the drug resistance of ivermectin seriously affects its application. How to reduce the drug resistance of ivermectin and increase its application scope and effect is a technical problem that needs to be solved urgently by those skilled in the art.

[0004] Juglone, chemical name: 5-hydroxy-1,4-naphthalenedione, belongs to naphthoquinone compounds, CAS: 481-39-0, molecular formula C10H6O3. Juglone is an important active substance existing in Juglans mandshurica and walnut, plants of the genus Juglandaceae, and is a secondary metabolite produced in the long-term natural selection and evolution of plants. Juglone can have a variety of effects on cells, including damaging DNA, inhibiting transcription, reducing pH3 protein levels, and inducing cell death. At present, juglone is mainly used for the treatment of liver cancer (see invention patent CN108703964A), gastric cancer (see Yu Pingping et al. Effects of juglone on proliferation, invasion and glycolysis of gastric cancer SGC-7901 cells [J]. Chinese Journal of Traditional Chinese Medicine and Pharmacy, 2022, 29(05):761-766.), and lung cancer (see Hao Xinping, Liu Zuoning. Effects of juglone on lung cancer NCL-H460 cells [J]. Journal of Weifang Medical College, 2022, 44(03):181-183.DOI:10.16846 / j.issn.1004-3101.2022.03.0 05.) and the treatment of cervical cancer (see the literature Zhao Xingyu et al. Juglone inhibits the growth of cervical cancer cells and promotes apoptosis by promoting the ubiquitination and degradation of c-Myc [J]. Journal of Southern Medical University, 2022, 42(07): 1026-1031.). Regarding mites, only juglone is disclosed to have a therapeutic effect on Tetranychus cinnabarinus (see the literature Liu Yan et al. Study on the contact toxicity of juglone in walnut green peel to Tetranychus cinnabarinus [J]. Journal of Beijing Agricultural College, 2015, 30(04): 59-62. DOI: 10.13473 / j.cnki.issn.1002-3186.2015.0034.). It is well known to researchers in this field that Tetranychus cinnabarinus belongs to plant mites, and its prevention and control mainly uses chemical pesticides. Unlike the prevention and control of animal mite diseases, there is no literature disclosing that juglone has the effect of preventing and controlling animal mite diseases. There is no document that discloses that the combined use of juglone and ivermectin has a synergistic effect.

[0005] In response to the above technical problems, the present invention combines juglone and ivermectin for the first time. Compared with single agents, the combined use of the composition for treating animal mite diseases has a synergistic effect in killing mites, improves the prevention and control effect, reduces the losses caused by mites, promotes the recovery of damaged fur, reduces fur damage, and can avoid potential drug resistance caused by the use of a single compound, reducing residues and environmental pollution. Summary of the invention

[0006] In order to solve the problems existing in the prior art, the present invention provides a pharmaceutical composition for preventing or treating animal mite diseases, which has the advantages of obvious synergistic effect, long lasting effect and environmental friendliness. The specific technical scheme is as follows:

[0007] The primary purpose of the present invention is to provide a pharmaceutical composition for preventing or treating animal acariasis, wherein the pharmaceutical composition comprises juglone and ivermectin, and the mass ratio of juglone to ivermectin is (1-10): (1-10).

[0008] Preferably, the pharmaceutical composition is composed of juglone and ivermectin, and the mass ratio of juglone to ivermectin is (1-10): (1-10).

[0009] Preferably, the mass ratio of juglone to ivermectin is (1-5):(1-10).

[0010] Preferably, the mass ratio of juglone to ivermectin is 1:10.

[0011] Preferably, the mass ratio of juglone to ivermectin is 1:1.

[0012] Preferably, the mass ratio of juglone to ivermectin is 5:1.

[0013] Preferably, the mites include one or more of itch mites and scabies mites.

[0014] Preferably, the mite is the rabbit itch mite.

[0015] Preferably, the composition for treating animal acariasis is added with pharmaceutically acceptable excipients to be prepared into powders, injections, external ointments, emulsions, and sprays.

[0016] The second object of the present invention is to provide the use of the pharmaceutical composition in the preparation of drugs for preventing animal acariasis.

[0017] The third object of the present invention is to provide the use of the pharmaceutical composition in the preparation of drugs for treating animal acariasis.

[0018] The beneficial effects of the present invention are as follows: in the pharmaceutical composition of the present invention, juglone and ivermectin are combined for the first time, and compared with a single agent, the combined use of the composition for treating animal mite disease has a synergistic effect in killing mites, improves the prevention and control effect, reduces the loss caused by mites, promotes the recovery of damaged fur, reduces fur damage, and significantly reduces the dosage of ivermectin, can avoid potential drug resistance caused by the use of a single compound, and reduces residues and environmental pollution. DETAILED DESCRIPTION

[0019] In order to better understand the present invention, the above contents of the present invention are further described in detail below through specific implementation modes, but this should not be construed as limiting the present invention.

[0020] The experiments disclosed in the present invention, unless otherwise specified, all adopt conventional methods;

[0021] The drugs involved in the present invention, unless otherwise specified, can be purchased from the market.

[0022] In the embodiments of the present invention, DMSO is used as a solvent to promote the dissolution of the drug. However, those skilled in the art should understand that any solvent used in the art that can achieve the dissolution of the drug can be applied.

[0023] Example 1

[0024] The drug combination of the present invention is provided as follows:

[0025] Mix 500 μg of juglone and 500 μg of ivermectin, dissolve in 100 μL of dimethyl sulfoxide, mix well, then add water to 10 mL, and make the volume uniform.

[0026] Example 2

[0027] The drug combination of the present invention is provided as follows:

[0028] Mix 167 μg of juglone and 835 μg of ivermectin, dissolve in 100 μL of dimethyl sulfoxide, mix well, then add water to 10 mL, and make the volume uniform.

[0029] Example 3

[0030] The drug combination of the present invention is provided as follows:

[0031] Mix 90.9 μg of juglone and 909.9 μg of ivermectin, dissolve in 100 μL of dimethyl sulfoxide, mix well, then add water to 10 mL, and make the volume uniform.

[0032] Example 4

[0033] The drug combination of the present invention is provided as follows:

[0034] Mix 835 μg of juglone and 167 μg of ivermectin, dissolve in 100 μL of dimethyl sulfoxide, mix well, then add water to 10 mL, and make the volume uniform.

[0035] Example 5

[0036] The drug combination of the present invention is provided as follows:

[0037] Mix 909.9 μg of juglone and 90.9 μg of ivermectin, dissolve in 100 μL of dimethyl sulfoxide, mix well, then add water to 10 mL, and make the volume uniform.

[0038] Example 6 Determination of the acaricidal activity of the combination of juglone and ivermectin against rabbit itch mites

[0039] 1. Experimental Methods and Materials

[0040] New Zealand white rabbits naturally infected with itch mites were collected from farms, and itch mites were collected and cultured at 25±1℃ and RH≥80%. The experimental mites were used only once and then killed with boiling water.

[0041] Experimental groups: drug combination groups with different ratios, juglone group, ivermectin group, and 1% dimethyl sulfoxide group.

[0042] Experimental method: After diluting the drug with water, take 0.35 ml of the drug solution to soak the bottom of the plate with the filter paper inside. Use 1% DMSO solution as solvent control. Use a worm picking needle to pick the mites to the center of the filter paper in the plate, seal it, and culture it in an incubator (25±1℃, RH≥80%) for 24 hours. Count the number of deaths under a microscope, and consider those that do not move as dead. The experiment was repeated three times.

[0043] The synergistic effect of acaricide mixtures was calculated according to the Wadley method. 50 . Based on each single dose EC 50 The value was determined, and the appropriate initial screening concentration was selected. The in vitro acaricidal activity of the mixture was screened at a mass ratio (active component A: active component B) of 1:1, 1:5, 1:10, 10:1, and 5:1. Finally, the synergistic coefficient of the mixture of different agents was calculated using the Wadley formula. SR>1.5 indicates synergism; SR<0.5 indicates antagonism; SR between 0.5 and 1.5 indicates additive effect.

[0044] 1% DMSO

[0045] 2. Experimental results

[0046] Table 1 Acaricidal activity of juglone and ivermectin combination

[0047]

[0048]

[0049] From the results in Table 1, it can be seen that the synergistic effect of juglone and ivermectin mixed at 1:1, 1:10, and 5:1 is obvious, and the synergistic coefficient SR is greater than 1.5. Among them, the synergistic coefficient of juglone and ivermectin is the highest when the ratio is 1:10, and the mixing of juglone and ivermectin at 1:5 and 10:1 is additive.

[0050] In summary, the present invention combines juglone and ivermectin for the first time, and the prepared pharmaceutical composition has a high lethality rate against mites, and has a good therapeutic effect on animal mite diseases caused by itch mites and scabies mites. Compared with a single dose, the combined use of the composition for treating animal mite diseases has a synergistic effect in killing mites, improves the prevention and control effect, reduces the loss caused by mites, promotes the recovery of damaged fur, reduces fur damage, and can avoid potential drug resistance caused by the use of a single compound, reduces residues and environmental pollution, and also reduces the amount of chemically synthesized active ingredients. In addition, the composition is safe for animals and meets safety requirements.

Claims

1. A pharmaceutical composition for treating animal acariasis, characterized in that: The pharmaceutical composition is composed of juglone and ivermectin, the mass ratio of juglone to ivermectin is 1:10, 1:1 or 5:1, and the animal mite disease is scabies or itch mite disease.

2. The pharmaceutical composition for treating animal acariasis according to claim 1, characterized in that: The composition for treating animal acariasis is added with pharmaceutically acceptable adjuvants to be prepared into powder, injection, external ointment, emulsion or spray.

3. Use of the pharmaceutical composition as claimed in claim 1 in the preparation of drugs for treating animal acariasis.

Citation Information

Cited By

  • Compound ivermectin juglone liniment as well as preparation method and application thereof

    CN120324448A